Ulcerative colitis (UC) is a chronic inflammatory bowel disease of unknown aetiology
affecting the colon and rectum. Multiple factors, such as genetic background, environmental …

Therapeutic drug monitoring (TDM) of biologics is a rapidly evolving field. We aimed to
provide a consensus statement regarding the clinical utility of TDM for biologics in …

Ulcerative colitis (UC) is an idiopathic inflammatory disorder. These guidelines indicate the
preferred approach to the management of adults with UC and represent the official practice …

Background & Aims Therapeutic drug monitoring (TDM) is widely available for biologic
therapies in patients with inflammatory bowel disease (IBD). We reviewed current data and …

Tumor necrosis factor-α (TNFα) antagonists have advanced the management of
inflammatory bowel diseases patients leading to an improvement of patient's quality of life …

Background Gut-selective blockade of lymphocyte trafficking by vedolizumab may constitute
effective treatment for ulcerative colitis. Methods We conducted two integrated randomized …

Objectives A systematic review was conducted to explore the immunogenicity of biologic
agents across inflammatory diseases and its potential impact on efficacy/safety. Methods …

Therapeutic drug monitoring (TDM), which involves measurement of drug or active
metabolite levels and anti-drug antibodies, is a promising strategy that can be used to …

Background Therapeutic drug monitoring (TDM) in inflammatory bowel disease (IBD)
patients receiving anti‐tumour necrosis factor (TNF) agents can help optimise outcomes …

Background & Aims The medical management of ulcerative colitis (UC) has improved
through the development of new therapies and novel approaches that optimize existing …